首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   2433篇
  免费   276篇
  国内免费   75篇
儿科学   12篇
妇产科学   4篇
基础医学   203篇
口腔科学   4篇
临床医学   108篇
内科学   793篇
神经病学   3篇
特种医学   256篇
外国民族医学   17篇
外科学   170篇
综合类   240篇
现状与发展   1篇
预防医学   51篇
药学   119篇
中国医学   33篇
肿瘤学   770篇
  2023年   60篇
  2022年   53篇
  2021年   137篇
  2020年   106篇
  2019年   204篇
  2018年   161篇
  2017年   142篇
  2016年   77篇
  2015年   147篇
  2014年   306篇
  2013年   194篇
  2012年   145篇
  2011年   130篇
  2010年   95篇
  2009年   108篇
  2008年   111篇
  2007年   88篇
  2006年   88篇
  2005年   93篇
  2004年   68篇
  2003年   26篇
  2002年   33篇
  2001年   44篇
  2000年   27篇
  1999年   27篇
  1998年   15篇
  1997年   23篇
  1996年   12篇
  1995年   19篇
  1994年   20篇
  1993年   4篇
  1992年   6篇
  1991年   3篇
  1990年   6篇
  1989年   2篇
  1986年   1篇
  1984年   1篇
  1981年   1篇
  1908年   1篇
排序方式: 共有2784条查询结果,搜索用时 15 毫秒
1.
《中国现代医生》2020,58(29):24-27+封三
目的 探讨肝癌组织中LncRNA TINCR 表达水平对术后长期生存的影响。方法 回顾性分析2013 年4 月~2016 年2 月间在本院接受手术治疗的157 例肝细胞肝癌患者的临床资料。RT-PCR 法检测肝癌标本内LncRNA TINCR 表达水平,采用ROC 曲线和Kaplan-Meier 法分析LncRNA TINCR 表达水平对肝癌术后长期生存的影响。结果 肝癌组织LncRNA TINCR 表达水平对术后长期生存预测的曲线下面积(AUC)为0.812,特异度为73.77%,灵敏度为79.17%,最佳判读值为1.89(P<0.0001)。根据ROC 曲线分析结果,将肝癌组织LncRNA TINCR 相对表达水平大于1.89 的93 例(59.24%)患者纳入高表达组,而肝癌组织LncRNA TINCR 相对表达水平小于或等于1.89的64 例(40.76%)患者纳入低表达组。Kaplan-Meier 法生存分析发现高表达组术后3 年内有76 例患者死亡,3 年总生存率为18.28%(17/93);低表达组术后3 年内有20 例患者死亡,3 年总生存率为68.75%(44/64),低表达组3 年总生存率明显优于高表达组(P<0.0001,两组间死亡风险比为3.7534,95%可信区间为2.5158~5.6000)。结论 肝癌组织LncRNA TINCR 表达水平与肝癌术后长期生存显著相关,LncRNA TINCR 表达水平升高则预示着预后不佳。  相似文献   
2.
3.
目的:探讨miR-26b参与原发性肝细胞肝癌(HCC)侵袭的机制。方法:在细胞培养液中培养人肝细胞系HL-7702和HCC细胞各系Hepb-3、HuH-7、MHCC97-L、MHCC97-H。实时荧光定量PCR法(qRT-PCR)检测miR-26b的表达水平;用miR-26b mimics、miR-26b inhibitors和Notch1-siRNA分别转染HCC细胞;MTT实验检测转染后HCC细胞的活力;采用Western blot检测Notch1受体蛋白表达水平的变化;Transwell小室测定不同处理后的HCC细胞的侵袭能力。结果:人正常肝细胞系HL-7702和HCC细胞系Hepb-3、HuH-7、MHCC97-L、MHCC97-H中的miR-26b相对表达含量随其侵袭和迁移能力的升高而依次下降;抑制miR-26b的表达,Notch1受体蛋白表达明显增高,而此时HCC细胞的侵袭性显著增强;相反,上调miR-26b的表达,Notch1受体蛋白表达明显降低,而HCC细胞侵袭性显著下降;miR-26b可能通过调控Notch1信号通路调节HCC细胞侵袭性。结论:miR-26b通过负调控Notch1信号通路抑制HCC细胞侵袭能力,为HCC侵袭的机制奠定了理论基础,miR-26b可能成为HCC治疗的新靶点。  相似文献   
4.
Objectives: This study aimed to investigate the expression of SOX2, SOX9, p53, and β-catenin in hepatocellular carcinoma (HCC) and their correlation with clinicopathological parameters of prognostic importance. Materials and Methods: Seventy-five patients were enrolled in this study. All patients had full clinical and follow-up data and available paraffin blocks. Immunohistochemical analysis was performed and correlated with clinicopathological factors and patient survival. Results: We detected the positive expression of SOX2, SOX9, p53, and β-catenin in 76%, 50.7%, 50.7%, and 77.9% of HCC specimens respectively. All studied markers showed a significant increase in the expression in tumor tissue specimens compared to non-tumor tissue. Both SOX2 and SOX9 expressions were significantly associated with adverse prognostic factors in HCC. Significant positive correlations were found between SOX2 and SOX9 and both p53 and β-catenin expression (r= 0.528, 0.485 and; r = 0.253, 0.327, respectively; p < 0.0001 for both of them). Regarding survival, we found that HCC patients with positive SOX2 and SOX9 expressions had significantly shorter overall survival (p=0.0001, each). Additionally, larger tumor size, tumor grade, high stage, tumor multiplicity, presence of cirrhosis, tumor necrosis, high p53 expression, and positive β-catenin expression were independent predictors of worse survival. A multivariate Cox analysis revealed that tumor grade, stage, p53, and SOX2 expression were independent predictors of unfavorable prognosis in overall survival (p=0.0001, p=0.0001,p=0.033; and p=0.003, respectively). Conclusions: Our findings might provide an insight into SOX2 and SOX9’s role in HCC and suggest that SOX2 might be targeted for HCC therapy.  相似文献   
5.

Purpose

To evaluate the feasibility of a same-day yttrium-90 (90Y) radioembolization protocol with resin microspheres (including pretreatment angiography, lung shunt fraction [LSF] determination, and radioembolization) for the treatment of hepatocellular carcinoma (HCC) and liver metastases.

Materials and Methods

All same-day radioembolization procedures performed over 1 y (February 2017 to January 2018) were included in this single-institutional retrospective analysis, in which 34 procedures were performed in 26 patients (median age, 63 y; 13 women), 19 with liver metastases and 7 with HCC. Yttrium-90 treatment activities were calculated by body surface area method. Tumor imaging response was assessed by Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 for liver metastases and modified RECIST for HCC. Clinical side effects and adverse events were graded per Common Terminology Criteria for Adverse Events version 4.0.

Results

All planned cases were technically successful, and no cases were canceled for elevated LSF or vascular anatomic reasons. Pretreatment angiography modified the planned 90Y treatment activity in 1 case in which vascular anatomy required a lobar-dose split into 2 for segmental infusions. In 18% of cases, patients were briefly admitted after the procedure for observation or symptom management. Imaging evaluation of initial efficacy at 1 month demonstrated partial response in 25% and stable disease in 67% of patients with liver metastases and partial/complete response in 43% and stable disease in 14% of patients with HCC. Grade ≥ 3 adverse events occurred in 6% of cases, with no systemic therapy–limiting toxicities. The mean total procedure time was 4.2 hours.

Conclusions

A same-day 90Y radioembolization protocol with resin microspheres is feasible in select patients, which can expedite cancer therapy.  相似文献   
6.
7.
肝动脉化疗栓塞术治疗肝癌的临床与病理的联系   总被引:1,自引:0,他引:1  
梁力建  林汉良 《癌症》1993,12(2):148-150
作者将9例肝动脉化疗栓塞术(HAE)后二期切除的肝癌标本,多处切片作病理检查,结合病人的临床过程分析HAE的治疗作用,肝癌包膜对HAE的影响,HAE的效果及HAE后手术的时机等。作者认为,HAE对肝癌的治疗效果是姑息性的,故HAE后应争取在30~60天内再手三术探查,争取切除肿瘤。否则,HAE后肝癌复发的可能性极大。  相似文献   
8.
柏凯  梁平 《消化外科》2006,5(2):115-118
目的探讨原发性肝细胞癌(HCC)患者外周血的Glypican-3(GPC-3)mRNA检测用于诊断HCC早期微转移的可行性。方法采用巢式逆转录聚合酶链反应(RT-PCR)技术检测39例原发性肝细胞癌(HCC)、19例肝炎和肝硬化、10例转移性肝癌、10例肝血管瘤患者、19例健康献血员外周血GPC-3mRNA水平。结果HCC患者外周血中,GPC-3mRNA的检出率为62%(24/39),GPC-3mRNA的检出率与肿瘤直径77%(17/22)、癌结节数目67%(19/24)、临床TNM分期76%(19/25)、门静脉癌栓90%(9/10)、远处转移100%(6/6)等临床参数密切相关。GPC-3mRNA在转移性肝癌、肝炎和肝硬化、肝血管瘤患者及健康献血员外周血中均未检出。结论巢式RT—PCR检测HCC患者外周血单核细胞GPC-3mRNA是一种早期发现原发性肝细胞癌血道播散的可靠而又敏感的实验方法。  相似文献   
9.
A case of small fibrolamellar hepatocellular carcinoma (HCC) coexistent with a HCC of common type is herein reported. A 56-year-old man was diagnosed as having multi-nodular type HCC with liver cirrhosis. The serum alpha-fetoprotein (AFP) level was slightly increased. The patient underwent a partial caudate lobectomy and lateral segmentectomy. Histologically, both resected tumors were small HCCs measuring less than 2 cm in diameter. One was a fibrolamellar type located in the caudate lobe, while the other was the common type in the lateral segment of the liver. Positive immunohistochemical staining for AFP was observed in the tumor cells of the HCC of common type but was not observed in the fibrolamellar HCC. We also reviewed previously reported cases of fibrolamellar HCC in Japan, and discussed the clinicopathologic implications of this disease.  相似文献   
10.
从人肝癌组织中提取总RNA,RT—PCR合成hTIMP-1的全长cDNA,克隆到腺病毒载体AdEasy系统的穿梭质粒pAdTraek—CMV上,与骨架质粒pAdEasy-1在BJ5183受体菌中进行同源重组,成功构建含hTIMP-1全长eDNA的重组腺病毒载体,经293细胞的包装、扩增,生成含hTIMP-1基因的重组腺病毒AdhTIMP-1并实现体外表达,为进一步研究肝癌浸润和转移机理以及肝癌的基因治疗提供实验基础。  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号